TD Asset Management Inc Sells 34,746 Shares of Vaxcyte, Inc. $PCVX

TD Asset Management Inc reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 8.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 363,734 shares of the company’s stock after selling 34,746 shares during the period. TD Asset Management Inc’s holdings in Vaxcyte were worth $16,783,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. EverSource Wealth Advisors LLC grew its holdings in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares during the period. CWM LLC grew its holdings in Vaxcyte by 9.0% in the fourth quarter. CWM LLC now owns 2,840 shares of the company’s stock worth $131,000 after purchasing an additional 234 shares during the period. Harbor Capital Advisors Inc. grew its holdings in Vaxcyte by 0.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 31,274 shares of the company’s stock worth $1,443,000 after purchasing an additional 252 shares during the period. PNC Financial Services Group Inc. grew its holdings in Vaxcyte by 3.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 14,917 shares of the company’s stock worth $688,000 after purchasing an additional 514 shares during the period. Finally, Allworth Financial LP grew its holdings in Vaxcyte by 148.9% in the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after purchasing an additional 731 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Down 2.2%

NASDAQ:PCVX opened at $46.33 on Tuesday. The company’s 50 day moving average price is $55.04 and its 200-day moving average price is $52.73. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00. The stock has a market cap of $6.69 billion, a price-to-earnings ratio of -6.73 and a beta of 1.24.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter in the previous year, the firm posted ($1.04) EPS. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -7.56 earnings per share for the current year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CAO Elvia Cowan sold 3,000 shares of the stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total transaction of $180,000.00. Following the sale, the chief accounting officer directly owned 28,975 shares in the company, valued at approximately $1,738,500. This trade represents a 9.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $49.52, for a total value of $111,420.00. Following the sale, the chief operating officer owned 158,494 shares in the company, valued at approximately $7,848,622.88. This represents a 1.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 11,892 shares of company stock worth $670,901. Company insiders own 3.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PCVX. BTIG Research upped their price objective on shares of Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Finally, Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.